Nexiam Iv (Esomeprazole)

Esomeprazole, the active ingredient in Nexiam Iv, is a proton pump inhibitor presented as an intravenous solution for intravenous use. It treats acid‑related disorders such as erosive esophagitis, gastro‑oesophageal reflux disease and helps prevent stress‑related mucosal damage in hospitalized patients.

GNH USA supplies Nexiam Iv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Esomeprazole acts on the gastric proton pump to reduce acid secretion, making it useful for several acid‑related conditions.

- Erosive esophagitis: promotes healing of damaged esophageal tissue by lowering gastric acidity. - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and prevents further esophageal injury through sustained acid suppression. - Prevention of stress‑related mucosal damage: reduces the risk of gastrointestinal bleeding in critically ill patients by inhibiting acid secretion.

Adverse reactions may occur with any medication and should be monitored by healthcare professionals.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Nausea: feeling of queasiness that may be transient. - Diarrhea: loose stools occurring during treatment. - Abdominal pain: discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing requiring immediate care. - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Hepatic enzyme elevation: increased liver function tests indicating possible liver stress. - Hypomagnesemia: low magnesium levels that may cause muscle cramps or arrhythmias. - Stevens‑Johnson syndrome: rare skin disorder with blistering and mucosal involvement.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters.

- Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate hepatic status: use with caution in patients with liver disease. - Review concomitant medications: potential interactions may affect efficacy. - Monitor electrolytes: especially magnesium during prolonged therapy. - Observe for signs of infection: especially C. difficile in at‑risk patients. - Store at ambient temperature: keep below 25°C, protect from moisture and light, and retain in original packaging.

Esomeprazole can alter the absorption or metabolism of several drugs; careful review is required.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased plasma concentrations, compromising antiviral efficacy. - Rilpivirine: lowered exposure, potentially reducing HIV suppression.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Methotrexate: reduced renal clearance, may raise toxicity risk. - Digoxin: increased serum levels, necessitating dose adjustment.